Company intelligence
AAVantgarde
Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease
Biotechnology Research
76 employees
2 public signals
About AAVantgarde
AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.
Verified activity
Signals from AAVantgarde
2 published signals
Presence & Recognition
AAVantgarde released a new video produced by investor Forbion featuring CEO Natalia Misciattelli discussing the company's mission, progress, and the potential of genetic medicines.
Reported by AAVantgarde
People
AAvantgarde welcomed Megan Zoschg Canniere as its new Chief of Regulatory and Quality Officer.
Reported by AAVantgarde